The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

PCAT4  -  prostate cancer associated transcript 4...

Homo sapiens

Synonyms: GDEP, PCA4, PCAN1
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of GDEP


Psychiatry related information on GDEP

  • Environmental factors, such as dietary habits, may play a major role in the causation of prostate cancer [6].
  • This pilot study explored the feasibility and efficacy of coping skills training (CST), an intervention developed to enhance coping with treatment side effects in a sample of African American prostate cancer survivors and their intimate partners [7].
  • PATIENTS AND METHODS: In all, 121 men undergoing RRP for clinically localized prostate cancer were prospectively evaluated for short-term HRQoL using an acute Short Form-12 version-2 Physical and Mental Health Survey Acute Form before and serially each week from 1 to 6 weeks after RRP [8].
  • PURPOSE: Many clinicians lack resources to engage patients in shared decision making for prostate cancer screening [9].
  • METHODS: Statistical tools from classical measurement theory and factor analytic methods were used to evaluate the psychometric properties of the Prostate Cancer Outcomes Study disease-specific scales [10].

High impact information on GDEP

  • Peroxisome Proliferator-Activated Receptor {gamma} Regulates E-Cadherin Expression and Inhibits Growth and Invasion of Prostate Cancer [11].
  • Overexpression of both genes has been reported in high-grade, androgen-resistant prostate cancer [12].
  • These results indicate that SOX9 in prostate basal cells supports the development and maintenance of the luminal epithelium and that a subset of prostate cancer cells may escape basal cell requirements through SOX9 expression [13].
  • However, AR-mediated transcriptional activity in stromal cells isolated from prostate cancer was reduced compared with stromal cells isolated from benign prostate and continued to be reduced when cocultured with tumor-derived prostate epithelial cells [14].
  • Thus, the ability of epithelial cells to modulate coregulator recruitment to the AR transcriptional complex on androgen-responsive genes seems altered in the stromal microenvironment of prostate cancer [14].

Chemical compound and disease context of GDEP


Biological context of GDEP


Anatomical context of GDEP

  • We further characterize PCAN1 expression in the prostate cell lines RWPE1, RWPE2, and LnCAP FGC [22].
  • In addition, normal prostate epithelial cells co-cultured with normal prostate stromal cells did not exhibit PCAN1 expression at any time [22].
  • Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer [23].
  • On the basis of this knowledge, the isolation and characterization of prostate cancer stem cells may now be possible and could provide an explanation for the known clinical and molecular heterogeneity of human prostate cancer [24].
  • Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique [25].

Associations of GDEP with chemical compounds


Other interactions of GDEP


Analytical, diagnostic and therapeutic context of GDEP

  • A total of 11 htSNPs (including COMT Val(158)Met) were selected based on the resequencing and dense genotyping approach of the Breast and Prostate Cancer Cohort Consortium. htSNPs were genotyped in a population-based, case-control study in Poland (1,995 cases and 2,296 controls) [32].
  • METHODS: In a retrospective cohort study, we determined the association between receipt of a PHE and cancer testing in a population-based sample of enrollees in a Washington State health plan who were aged 52 to 78 years and eligible for colorectal, breast, or prostate cancer screening in 2002-2003 (N = 64 288) [3].
  • Analysing prostate cancer biopsies by immunohistochemistry we found iNOS protein expression in tumor cells strongly paralleled by nitrotyrosine suggesting that iNOS is fully active [27].
  • Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer [33].
  • Furthermore, WA potently inhibits the chymotrypsin-like activity of a purified rabbit 20S proteasome (IC50=4.5 microM) and 26S proteasome in human prostate cancer cultures (at 5-10 microM) and xenografts (4-8 mg/kg/day) [34].


  1. GDEP, a new gene differentially expressed in normal prostate and prostate cancer. Olsson, P., Bera, T.K., Essand, M., Kumar, V., Duray, P., Vincent, J., Lee, B., Pastan, I. Prostate (2001) [Pubmed]
  2. A new human retrovirus associated with prostate cancer. Fan, H. Proc. Natl. Acad. Sci. U.S.A. (2007) [Pubmed]
  3. Delivery of cancer screening: how important is the preventive health examination? Fenton, J.J., Cai, Y., Weiss, N.S., Elmore, J.G., Pardee, R.E., Reid, R.J., Baldwin, L.M. Arch. Intern. Med. (2007) [Pubmed]
  4. Suicide Gene Therapy With Adenoviral Delivery of HSV-tK Gene for Patients With Local Recurrence of Prostate Cancer After Hormonal Therapy. Nasu, Y., Saika, T., Ebara, S., Kusaka, N., Kaku, H., Abarzua, F., Manabe, D., Thompson, T.C., Kumon, H. Mol. Ther. (2007) [Pubmed]
  5. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience. Hom, J.J., Coakley, F.V., Simko, J.P., Lu, Y., Qayyum, A., Westphalen, A.C., Schmitt, L.D., Carroll, P.R., Kurhanewicz, J. Radiology (2007) [Pubmed]
  6. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Kurahashi, N., Iwasaki, M., Sasazuki, S., Otani, T., Inoue, M., Tsugane, S. Cancer Epidemiol. Biomarkers Prev. (2007) [Pubmed]
  7. Facilitating research participation and improving quality of life for African American prostate cancer survivors and their intimate partners : a pilot study of telephone-based coping skills training. Campbell, L.C., Keefe, F.J., Scipio, C., McKee, D.C., Edwards, C.L., Herman, S.H., Johnson, L.E., Colvin, O.M., McBride, C.M., Donatucci, C. Cancer (2007) [Pubmed]
  8. A prospective evaluation of the short-term impact and recovery of health-related quality of life in men undergoing radical prostatectomy. Kouba, E., Hubbard, J.S., Moore, D., Wallen, E.M., Pruthi, R.S. BJU Int. (2007) [Pubmed]
  9. Patient education on prostate cancer screening and involvement in decision making. Krist, A.H., Woolf, S.H., Johnson, R.E., Kerns, J.W. Annals of family medicine (2007) [Pubmed]
  10. Should function and bother be measured and reported separately for prostate cancer quality-of-life domains? Reeve, B.B., Potosky, A.L., Willis, G.B. Urology (2006) [Pubmed]
  11. Peroxisome Proliferator-Activated Receptor {gamma} Regulates E-Cadherin Expression and Inhibits Growth and Invasion of Prostate Cancer. Annicotte, J.S., Iankova, I., Miard, S., Fritz, V., Sarruf, D., Abella, A., Berthe, M.L., No??l, D., Pillon, A., Iborra, F., Dubus, P., Maudelonde, T., Culine, S., Fajas, L. Mol. Cell. Biol. (2006) [Pubmed]
  12. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Murphy, A.J., Hughes, C.A., Barrett, C., Magee, H., Loftus, B., O'Leary, J.J., Sheils, O. Cancer Res. (2007) [Pubmed]
  13. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Wang, H., McKnight, N.C., Zhang, T., Lu, M.L., Balk, S.P., Yuan, X. Cancer Res. (2007) [Pubmed]
  14. Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer. Cano, P., Godoy, A., Escamilla, R., Dhir, R., Onate, S.A. Cancer Res. (2007) [Pubmed]
  15. Natural and synthetic retinoids in prostate cancer. Pasquali, D., Rossi, V., Bellastella, G., Bellastella, A., Sinisi, A.A. Curr. Pharm. Des. (2006) [Pubmed]
  16. Ilimaquinone, a marine sponge metabolite, displays anticancer activity via GADD153-mediated pathway. Lu, P.H., Chueh, S.C., Kung, F.L., Pan, S.L., Shen, Y.C., Guh, J.H. Eur. J. Pharmacol. (2007) [Pubmed]
  17. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Sarosdy, M.F. Cancer (2007) [Pubmed]
  18. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Engel, J.B., Schally, A.V. Nature clinical practice. Endocrinology & metabolism (2007) [Pubmed]
  19. Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities? Lycette, J.L., Bland, L.B., Garzotto, M., Beer, T.M. Clinical genitourinary cancer (2006) [Pubmed]
  20. Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Canene-Adams, K., Lindshield, B.L., Wang, S., Jeffery, E.H., Clinton, S.K., Erdman, J.W. Cancer Res. (2007) [Pubmed]
  21. Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer. Howard, E.W., Ling, M.T., Chua, C.W., Cheung, H.W., Wang, X., Wong, Y.C. Clin. Cancer Res. (2007) [Pubmed]
  22. Expression and initial promoter characterization of PCAN1 in retinal tissue and prostate cell lines. Cross, D., Reding, D.J., Salzman, S.A., Zhang, K.Q., Catalona, W.J., Burke, J., Burmester, J.K. Med. Oncol. (2004) [Pubmed]
  23. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. Anderson, M.J., Shafer-Weaver, K., Greenberg, N.M., Hurwitz, A.A. J. Immunol. (2007) [Pubmed]
  24. Prostate stem cells: From development to cancer. Signoretti, S., Loda, M. Semin. Cancer Biol. (2007) [Pubmed]
  25. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. Ganswindt, U., Paulsen, F., Corvin, S., Hundt, I., Alber, M., Frey, B., Stenzl, A., Bares, R., Bamberg, M., Belka, C. Int. J. Radiat. Oncol. Biol. Phys. (2007) [Pubmed]
  26. Localization of a Prostate Cancer Predisposition Gene to an 880-kb Region on Chromosome 22q12.3 in Utah High-Risk Pedigrees. Camp, N.J., Farnham, J.M., Cannon-Albright, L.A. Cancer Res. (2006) [Pubmed]
  27. Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Cronauer, M.V., Ince, Y., Engers, R., Rinnab, L., Weidemann, W., Suschek, C.V., Burchardt, M., Kleinert, H., Wiedenmann, J., Sies, H., Ackermann, R., Kröncke, K.D. Oncogene (2007) [Pubmed]
  28. Re: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer: C. W. Ryan, D. Huo, L. M. Demers, T. M. Beer and L. V. Lacerna. J Urol 2006; 176: 972-978. Gilbert, S.M., Dunn, R.L., Wei, J.T. J. Urol. (2007) [Pubmed]
  29. Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. van den Bemd, G.J., Krijgsveld, J., Luider, T.M., van Rijswijk, A.L., Demmers, J.A., Jenster, G. Mol. Cell Proteomics (2006) [Pubmed]
  30. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Groskopf, J., Aubin, S.M., Deras, I.L., Blase, A., Bodrug, S., Clark, C., Brentano, S., Mathis, J., Pham, J., Meyer, T., Cass, M., Hodge, P., Macairan, M.L., Marks, L.S., Rittenhouse, H. Clin. Chem. (2006) [Pubmed]
  31. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Marks, L.S., Fradet, Y., Deras, I.L., Blase, A., Mathis, J., Aubin, S.M., Cancio, A.T., Desaulniers, M., Ellis, W.J., Rittenhouse, H., Groskopf, J. Urology (2007) [Pubmed]
  32. Comprehensive assessment of genetic variation of catechol-o-methyltransferase and breast cancer risk. Gaudet, M.M., Chanock, S., Lissowska, J., Berndt, S.I., Peplonska, B., Brinton, L.A., Welch, R., Yeager, M., Bardin-Mikolajczak, A., Garcia-Closas, M. Cancer Res. (2006) [Pubmed]
  33. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Fujita, T., Timme, T.L., Tabata, K., Naruishi, K., Kusaka, N., Watanabe, M., Abdelfattah, E., Zhu, J.X., Ren, C., Ren, C., Yang, G., Goltsov, A., Wang, H., Vlachaki, M.T., Teh, B.S., Butler, E.B., Thompson, T.C. Gene Ther. (2007) [Pubmed]
  34. The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry". Yang, H., Shi, G., Dou, Q.P. Mol. Pharmacol. (2007) [Pubmed]
WikiGenes - Universities